Genetically engineered mouse models (GEMMs) of lung cancer have greatly assisted in the functional characterization of genes implicated in human lung cancers. The *Kras^LSL-G12D/+^; p53^flox/flox^* (KP) GEMM of human LUAD faithfully mimics human KRAS-driven LUAD, displaying similarities at the molecular and histopathological level following intratracheal administration of viral vectors expressing Cre-recombinase^[@R11]^. We recently developed a CRISPR/Cas9-based *in vivo* genome engineering method to rapidly interrogate putative genetic driver events cooperating with oncogenic *Kras* to promote lung tumorigenesis in the KP model^[@R12]-[@R14]^.

Based on the fact that *KEAP1* is the third most frequently mutated gene in LUAD and on the high coincidence of *KEAP1* inactivating mutations and *KRAS*-mutation in human lung cancers^[@R3]^, we chose to target this gene in the KP model using CRISPR/Cas9 technology. KP mice were intratracheally infected with pSECC lentiviral vectors expressing sgRNAs against *Keap1* or *tdTomato* as a control ([Supplementary Fig 1a](#SD1){ref-type="supplementary-material"}). Mice infected with pSECC vectors expressing different sgRNAs targeting *Keap1* (hereafter, sgKeap1 mice) had significantly increased tumor burden and faster growth kinetics compared to sgTom mice, as determined by longitudinal micro-computed tomography (micro-CT; *p* \< 0.05, [Fig 1a](#F1){ref-type="fig"}). Consistent with the micro-CT data, histological assessment of tumor burden revealed a significant increase in sgKeap1 mice compared to controls (*p* \< 0.05, [Fig 1b](#F1){ref-type="fig"}). This analysis also showed a dramatic increase in high-grade tumors in sgKeap1 mice compared to controls ([Fig 1c](#F1){ref-type="fig"} and [Supplementary Fig 1b](#SD1){ref-type="supplementary-material"}, *p* \< 0.0001 for sgKeap1.2 grade 3 and *p* \< 0.001 for sgKeap1.4 grade 4). Furthermore, sgKeap1 tumors displayed increased proliferation as gauged by an increase in mitotic index (phospho-Histone H3; *p* \< 0.05, [Fig 1d](#F1){ref-type="fig"}).

To determine the status of the Keap1/Nrf2 pathway in sgKeap1 tumors, we performed immunohistochemical (IHC) analyses to assess whether loss of *Keap1* led to both increased nuclear localization of Nrf2 protein and cytoplasmic levels of its target gene Nad(p)h dehydrogenase quinone 1 (*Nqo1*). The majority (60%) of sgKeap1 tumors had increased nuclear localization of Nrf2 and dramatically higher levels of Nqo1 as compared to controls (*p \<* 0.0001, [Fig 1e,f](#F1){ref-type="fig"}). Importantly, nearly all tumors that stained positively for nuclear Nrf2 also contained higher levels of Nqo1 *(p* \< 0.0001, [Fig 1e](#F1){ref-type="fig"}). Furthermore, the increased levels of Nrf2 in sgKeap1 tumors correlated with significantly lower ROS-dependent oxidation of DNA as compared to control sgTom tumors ([Fig 1g](#F1){ref-type="fig"}). High throughput DNA sequencing of micro-dissected sgKeap1 tumors (sgKeap1.2 and sgKeap1.4) that stained positively for nuclear Nrf2 and Nqo1 revealed that these tumors predominantly contained frameshift LOF insertions or deletions (indels) in *Keap1*, supporting the IHC analysis indicating Nrf2 pathway activation ([Supplementary Fig 1c-e](#SD1){ref-type="supplementary-material"}). Additionally, we observed a clonal enrichment of such *Keap1* LOF alleles in a lymph node metastasis compared to its paired primary tumor^[@R15],[@R16]^ ([Supplementary Fig 1f-h](#SD1){ref-type="supplementary-material"}).

We next asked if NQO1 could act as a marker for NRF2 activated human *KEAP1/NRF2* mutant LUAD tumors. Targeted exome capture (top 50 mutated LUAD genes based on TCGA^[@R3]^) of 88 LUAD tumors from the NYU Center for Biospecimen Research and Development identified 10 *KEAP1* (11%), and 2 *NRF2* (2%) mutant tumors, as well as a significant correlation between *KEAP1/ NRF2* mutations and increased NQO1 staining ([Figure 1h](#F1){ref-type="fig"}; *p =* 0.0002; [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). These data suggest that NQO1 is a suitable biomarker for NRF2 activation in human LUAD.

To determine the role of Nrf2 and Keap1 in regulating proliferation and antioxidant pathways in LUAD, we used CRISPR/Cas9-mediated genome editing to develop isogenic KP-derived lung tumor cell lines with LOF mutations in *Nrf2* (KPN), *Keap1* (KPK), and sgTom controls (KP) ([Supplementary Fig 2a,b](#SD1){ref-type="supplementary-material"}; *n =* 2 cell lines per genotype). As expected, KPK cells had increased nuclear localization of Nrf2 and increased levels of Nrf2 transcriptional targets as assessed by both protein analysis (Gclc; [Supplementary Fig 2c](#SD1){ref-type="supplementary-material"}) and gene expression analysis (*Nqo1*, *Hmox1* and *Gclc*; [Supplementary Fig 2d](#SD1){ref-type="supplementary-material"}). These changes were also observed in KP but not KPN cells upon treatment with Nrf2 activators ([Supplementary Fig 2e-h](#SD1){ref-type="supplementary-material"}). To validate these results, we performed whole transcriptome analyses (RNA sequencing) and identified transcriptional signatures that clearly distinguished KP from KPK cell lines based on the activation of the Nrf2 transcriptional program ([Supplementary Fig 2i](#SD1){ref-type="supplementary-material"}; [Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

We next used this panel of genetically-defined cell lines to further explore the role of the Nrf2/Keap1 pathway in regulating the antioxidant response program. KPN cells had dramatically decreased cell viability in response to multiple agents known to cause oxidative stress compared to KP cells. By contrast, KPK cells showed resistance to all agents tested ([Supplementary Fig 3a-e](#SD1){ref-type="supplementary-material"}). These effects correlated with the total levels of the major cellular antioxidant glutathione in the different cell lines ([Supplementary Fig 3f,g](#SD1){ref-type="supplementary-material"}). The loss of viability of KPN cells in response to oxidative stress agents was rescued by antioxidant treatments ([Supplementary Fig 3h](#SD1){ref-type="supplementary-material"}) or by ectopic expression of a gain-of-function (GOF) allele of *Nrf2*^[@R17]^ (KPN-ix; [Supplementary Fig 3i-o](#SD1){ref-type="supplementary-material"}). Consistent with these results, both mouse and human *Keap1*/*KEAP1-*mutant cells displayed markedly lower ROS levels compared to wild-type (WT) cells ([Supplementary Fig 3p,q](#SD1){ref-type="supplementary-material"}). Interestingly, KPK cells grew faster than KP cells *in vivo* but not *in vitro* ([Supplementary Fig 4a-f](#SD1){ref-type="supplementary-material"}), suggesting a differential requirement of the Nrf2-antioxidant response during tumorigenesis *in vivo*. In addition, loss of *Keap1/KEAP1* in tumors and cells with WT *p53*^[@R18]^ accelerated tumorigenesis and growth suggesting that *Keap1* is a tumor suppressor in lung cancer progression independent of *p53* mutation status ([Supplementary Fig 5a-p](#SD1){ref-type="supplementary-material"}). These data indicate that Nrf2 levels dictate the differential antioxidant response to oxidative stress, which may provide a selective growth advantage *in vivo*.

To assess the relevance of these data derived from GEMM studies for human lung cancer, we performed an integrative analysis using a dataset of human LUAD patient samples (*n* = 548) from The Cancer Genome Atlas (TCGA)^[@R3]^, published Nrf2 datasets^[@R7],[@R19],[@R20]^ and our GEMM-derived Nrf2-driven transcriptional signature. First, we derived a core signature of 108 high confidence NRF2 target genes ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}) using published datasets. TCGA human LUAD tumors across various disease stages were investigated; the core NRF2 target genes were significantly upregulated in tumors from advanced stage IV disease (*p =* 0.028, [Fig 2a](#F2){ref-type="fig"}). Additionally, patients whose tumors were most associated with the NRF2 core target signature had significantly worse survival when compared to the rest of the TCGA LUAD cohort (*p =* 0.008, [Fig 2b](#F2){ref-type="fig"}). In order to evaluate the association between *KEAP1* mutations and NRF2 pathway activation, we used gene expression data from all TCGA human LUAD primary tumors to derive a *KEAP1-*mutant transcriptional signature ([Supplementary Fig 6a](#SD1){ref-type="supplementary-material"}). This signature was enriched in the core NRF2 target genes, multiple antioxidant pathways, and the NRF2 oncogenic signature^[@R18]^ (NFE2L2.V2; [Supplementary Fig 6b,c](#SD1){ref-type="supplementary-material"} and [Supplementary Table 4](#SD1){ref-type="supplementary-material"}). Ranking tumors by the strength of their correlation with this signature allowed for stratification of all LUAD TCGA patients into two sub-populations (*n* = 91 most-correlated 20%, *n* = 367 rest of the cohort). These sub-populations exhibited significantly different survival times (*p* = 0.012, [Fig 2c](#F2){ref-type="fig"}). Similar results were observed within the set of *KRAS*-mutant patients (*n* = 24 most-correlated 20%, *n* = 99 rest of cohort, *p* = 0.00013; [Supplementary Fig 6d](#SD1){ref-type="supplementary-material"}). We did not observe significant co-occurrence of *KEAP1*-mutant and *KRAS*-mutant patients within the TCGA cohort (*p* = 0.418). Additionally, within the top 20% of patients that correlate with our *KEAP1*-mutant signature and exhibit poor survival, we did not observe an enrichment for *KRAS*-mutant patients (*p* = 0.816) when compared to the background prevalence of *KRAS*-mutant patients in the TCGA cohort. Taken together, these data suggest that the poor survival of patients most correlated with the *KEAP1*-mutant signature cannot be attributed to an over-representation of *KRAS*-mutant patients.

Furthermore, high grade tumors (grades III/IV) and late stage tumors (clinical stage IV disease) were significantly enriched for the human *KEAP1*-mutant transcriptional signature ([Supplementary Fig 6e](#SD1){ref-type="supplementary-material"}; grade III/IV: *p* = 0.02; [Fig 2d](#F2){ref-type="fig"} stage IV: *p* = 0.038). Importantly, this signature was found to be independently prognostic in the TCGA LUAD cohort while controlling for other clinical covariates in a Cox proportional hazards model (HR = 1.22; univariate *p* = 0.029, multivariable *p* = 0.04, [Supplementary Table 5](#SD1){ref-type="supplementary-material"}) where higher enrichment for the signature was associated with significantly worse survival. We also did not detect an enrichment for *TP53* mutated patients in the *KEAP1*-mutant signature correlated cohort. Likewise, we did not observe a significant co-occurrence of *KEAP1*-mutant and *TP53*-mutant patients in the TCGA LUAD cohort (*p* = 0.115). To assess the translational potential of the GEMM results to human LUAD with *KEAP1* mutations, we performed a cross-species comparison of the *Keap1*-mutant transcriptional signatures. The GEMM *Keap1*-mutant signature ([Supplementary Fig 2i](#SD1){ref-type="supplementary-material"}) was significantly enriched in the human *KEAP1*-mutant signature ([Supplementary Fig 6f](#SD1){ref-type="supplementary-material"}). Furthermore, the GEMM-based signature could also stratify human patients with significantly different survival times (with correlated patients showing poor survival (*p* = 0.003, [Fig 2e](#F2){ref-type="fig"})).

Having established the importance of *KEAP1* mutations in mouse and human KRAS-driven LUAD, we sought to uncover potential therapeutic vulnerabilities in this genetic subtype of lung cancer. To this end, we performed a focused CRISPR/Cas9-based genetic screen to identify synthetic genetic interactions with *Keap1* mutations. A pool of lentiviruses expressing a focused CRISPR/Cas9 library was engineered to express sgRNAs against a panel of Nrf2 transcriptional targets and genes implicated in the Nrf2 antioxidant response (17 genes and 3 controls, 3-4 sgRNAs/gene, 65 sgRNAs total, [Supplementary Table 6](#SD1){ref-type="supplementary-material"} [Fig 3a](#F3){ref-type="fig"} and [Supplementary Fig 7a](#SD1){ref-type="supplementary-material"}). We infected KP or KPK cell lines (*n* = 2 per genotype) and assessed the relative depletion of sgRNAs after 14 population doublings to identify genes in which mutations selectively affected the growth of KPK compared to KP cells in culture (average relative depletion score threshold \<-0.3). Notably, out of 60 experimental sgRNAs across 17 genes, three out of four sgRNAs against *solute carrier family 1 member 5* (*Slc1a5*), a glutamine transporter^[@R21]^, fell below our threshold values and were depleted in KPK but not KP cells, suggesting that *Slc1a5* mutation selectively impairs the growth of *Keap1*-mutant cells ([Fig 3a](#F3){ref-type="fig"} and [Supplementary Fig 7a](#SD1){ref-type="supplementary-material"}). We next generated *Slc1a5*-mutant derivatives of KPK and human lung cancer cells with *KRAS* and *KEAP1* mutations (A549 and H2030). These cells displayed markedly decreased growth, while we observed no effect in *Keap1*-WT mouse (KP1, KP2) and human (H2009) cell lines upon mutation of *Slc1a5* ([Fig 3b-d](#F3){ref-type="fig"} and [Supplementary Fig 7b](#SD1){ref-type="supplementary-material"}). Furthermore, KPK cell lines were more sensitive to GPNA, a small molecule inhibitor of Slc1a5, compared to KP cell lines ([Fig 3e](#F3){ref-type="fig"} and [Supplementary Fig 7c](#SD1){ref-type="supplementary-material"}). The selective requirement of Slc1a5 function in KPK cell lines suggested a possible metabolic dependency of KPK cells on glutamine. Indeed, decreasing glutamine concentration in the media led to a robust suppression of growth in KPK cell lines with little effect on KP cell lines ([Fig 3f](#F3){ref-type="fig"} and [Supplementary Fig 7d](#SD1){ref-type="supplementary-material"}). The dependency of KPK cell lines on Slc1a5 and glutamine could be via the fueling of the tricarboxylic acid (TCA) cycle in the context of an increased glycolytic state^[@R22]^. Consistent with this possibility, we found that both KPK cell lines had higher glucose ([Supplementary Fig 7e](#SD1){ref-type="supplementary-material"}) and glutamine consumption ([Fig 3g](#F3){ref-type="fig"}) coupled with a marked increase in lactate excretion compared to KP cells ([Supplementary Fig 7e](#SD1){ref-type="supplementary-material"}). KPK cells also showed increased sensitivity to the glycolysis inhibitor 2-deoxy-D-glucose (2-DG; [Supplementary Fig 8a,b](#SD1){ref-type="supplementary-material"}). In addition, isotopic carbon labeled glucose (U13-Glucose) tracing revealed decreased contribution of glucose-derived carbons to TCA cycle intermediates in KPK cells compared to KP controls ([Supplementary Fig 8c-e](#SD1){ref-type="supplementary-material"}), which is not due to differences in the expression of pyruvate carboxylase (*Pcx*) and glutamine synthetase (*Glul*) between KPK and KP cells ([Supplementary Data Table 2](#SD1){ref-type="supplementary-material"}).

We next investigated whether increased glutamine utilization in KPK cell lines could be exploited as a metabolic liability. As glutaminase is the rate-limiting enzyme for glutamine utilization in the cell^[@R14],[@R23]^ ([Fig 4a](#F4){ref-type="fig"}), we tested two small molecule inhibitors of glutaminase: BPTES and CB-839^[@R21]^, the latter which is currently in phase I clinical trials for *KRAS*-mutant lung cancer ([Fig 4a,b](#F4){ref-type="fig"} and [Supplementary Fig 9a](#SD1){ref-type="supplementary-material"}). KPK cells were markedly more sensitive to both drugs compared to KP cells ([Fig 4c](#F4){ref-type="fig"}). In addition, a panel of human lung cancer cells containing *KEAP1* or GOF-*NRF2* mutations were sensitive to glutaminase inhibition while *KEAP1*-WT cells were largely resistant ([Fig 4d](#F4){ref-type="fig"} and [Supplementary Fig 9b](#SD1){ref-type="supplementary-material"}). Interestingly, pretreatment of KPK cells with glutamate, pyruvate or cell permeable alpha-ketoglutarate, but not the antioxidants Trolox or N-acetyl cysteine (NAC), rescued CB-839 sensitivity ([Supplementary Fig 9c-f](#SD1){ref-type="supplementary-material"}). These results suggest that glutaminase inhibition suppresses cell growth by blocking anaplerosis and not through loss of antioxidant production. To determine whether the sensitivity of KPK cells to glutaminase inhibition was dependent on hyperactive Nrf2 signaling, we transduced KP cells with lentiviruses expressing a GOF-*Nrf2* allele ([Supplementary Fig 3i-o](#SD1){ref-type="supplementary-material"}; [Supplementary Fig 10a,b](#SD1){ref-type="supplementary-material"}; KP-ix). Expression of GOF-Nrf2 in KP cells led to increased sensitivity to CB-839 ([Supplementary Fig 10c](#SD1){ref-type="supplementary-material"}). In addition, genetic complementation of *Keap1* in KPK cells reduced Nrf2 protein levels, expression of Nrf2 target genes, reversed the *in vivo* growth advantage of KPK cells, and rescued the viability of CB-839 treated KPK cells ([Supplementary Fig 10d-g](#SD1){ref-type="supplementary-material"}).

To investigate the therapeutic potential of targeting glutaminase in *Keap1-*mutant tumors *in vivo*, we transplanted KP and KPK cells subcutaneously and orthotopically (lung) in immunodeficient animals. Once tumors were established, we initiated treatment with either vehicle or CB-839 ([Supplementary Fig 11a](#SD1){ref-type="supplementary-material"}). Consistent with an earlier study^[@R14]^, we found that KP-derived tumors exhibited no response to CB-839 treatment ([Fig 4e](#F4){ref-type="fig"}-g and [Supplementary Fig 11b,c](#SD1){ref-type="supplementary-material"}). By contrast, KPK-derived subcutaneous and orthotopic tumors had dramatically decreased growth and established smaller final tumor weights in response to CB-839 treatment ([Fig 4e-g](#F4){ref-type="fig"} and [Supplementary Fig 11b,c](#SD1){ref-type="supplementary-material"}). Furthermore, transplanted KP-ix cells exhibited increased growth upon doxycycline-dependent induction of GOF-Nrf2, which was suppressed by glutaminase inhibition ([Fig 4h](#F4){ref-type="fig"} and [Supplementary Fig 11d](#SD1){ref-type="supplementary-material"}). Finally, we demonstrated that glutaminase inhibition suppressed the *in vivo* growth of KRAS-driven human LUAD cancer cell lines and patient-derived xenografts with *KEAP1* mutations, but had no effect on the growth of *KEAP1*-WT tumors ([Figure 4i](#F4){ref-type="fig"}; [Supplementary Fig 11e-I](#SD1){ref-type="supplementary-material"}; [Supplementary Table 7](#SD1){ref-type="supplementary-material"}). Taken together, these data suggest that glutaminase or other targets within this metabolic pathway are attractive therapeutic targets in *Keap1/Nrf2*-mutant LUAD. Furthermore, rational stratification of patients harboring mutations in *KEAP1* or *NRF2* may predict treatment response to glutaminase inhibitors.

In conclusion, we demonstrate that *Keap1* mutations activate the Nrf2 antioxidant program and cooperate with mutant *Kras* to drive LUAD progression, supporting the requirement for cancer cells to overcome oxidative stress barriers during tumorigenesis^[@R24]-[@R30]^. We hypothesize that the metabolic requirement for glutaminolysis in *KEAP1/NRF2*-mutant LUAD tumors may also present a therapeutic vulnerability in other cancers with genetic^[@R31]-[@R36]^, epigenetic^[@R37]-[@R39]^ or post-transcriptional^[@R17]^ alterations in the *KEAP1/NRF2* pathway. A recent study demonstrated that *KEAP1* loss potentiates resistance to multiple targeted therapies in EGFR- and RAS-driven cancers, highlighting the importance of our therapeutic strategy against *KRAS-KEAP1*-mutant lung cancer^[@R40]^. Furthermore, our findings provide unique insight into the therapeutic potential of targeting metabolic dependencies based on somatic variants by combining genetic and metabolic approaches to identify novel targets in translational oncology. Collectively, our study presents a novel CRISPR/Cas9-based precision medicine platform that can be used to characterize putative cooperating mutations and identify genotype-specific vulnerabilities in cancer.
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![Loss of *Keap1* stabilizes Nrf2 and accelerates lung tumorigenesis\
**a)** Micro-computed tomography (micro-CT) quantification of total tumor volume (mm^3^) of tumors from sgKeap1.4 (*n* = 5) or sgTom (*n* = 3) infected animals at 4 and 5 months post infection. **b)** Combined quantification of tumor burden (total tumor area/total lung area) in *Kras^LSL-G12D/+^; p53*^fl/fl^ (KP) animals after infection with pSECC lentiviruses. Left panel: tumor burden 21 weeks post infection of animals infected with control sgTom (*n* = 3) or sgKeap1.2 (*n* = 7). Right panel: tumor burden 21 weeks post infection of animals infected with control sgTom (*n* = 6) or sgKeap1.4 (*n* = 5). The asterisks indicate statistical significance obtained from comparing KP-sgKeap1 samples to KP-sgTom samples. **c)** Distribution of histological tumor grades in KP animals 21 weeks after infection with pSECC lentiviruses expressing: control (sgTom, KP; *n* = 7 mice), sgKeap1.2 (KP; *n* = 3 mice). **d)** Quantification of phospho-Histone H3 (pHH3) positive nuclei per mm^2^ to assess the mitotic index of tumor cells from lung tumors in KP animals 21 weeks after infection with pSECC lentiviruses expressing: control (sgTom, *n* = 14 tumors), or sgKeap1.2 (*n* = 50 tumors). **e)** Contingency tables demonstrating correlation between nuclear Nrf2 expression and Nqo1 expression. Top panel: quantified tumors obtained from control sgTom infected mice. Bottom panel: quantified tumors obtained from sgKeap1.2 infected mice (two-sided Fisher\'s exact test, \*\*\*\**p* \< 0.0001). **f)** Representative hematoxylin and eosin (H&E) and immunohistochemistry (IHC) staining of serial sections from lung tumors of mice 21 weeks after infection with pSECC-sgTom (top panel) or pSECC-sgKeap1.2 (bottom panel). First panels: representative overall lung tumor burden. Second panel: higher magnification H&E of representative tumors. Third panel: Nuclear Nrf2 IHC. Fourth panel: Nqo1 IHC. Note the accumulation of Nrf2 and Nqo1 occurs only in tumors from pSECC-sgKeap1.2 mice. Inset represents higher magnification. Scale bars are 100um. **g)** Oxidative stress index as judged by % 8-oxo-dG positive nuclei (*n* = 10 per genotype). All error bars denote s.e.m. Obtained from two-sided Student\'s *t*-test unless otherwise noted. \**p* \< 0.05, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001. **h)** *KEAP1/NRF2*-mutant versus WT human LUAD biopsy IHC for NQO1. All tumor samples were confirmed to be *KEAP1/NRF2* mutant via targeted exome sequencing (See [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Right legend depicts examples of staining criteria.](nihms901248f1){#F1}

![A *NRF2* target gene signature and a human derived *KEAP1*-mutant and predict human LUAD patient survival\
**a)** Empirical cumulative distribution function (CDF) plot showing correlation of individual tumors with the NRF2 core target signature across various clinical stages within the TCGA LUAD cohort. Each curve in the plot represents a unique clinical stage as depicted in the figure legend. Clinical stage IV tumors (*n* = 24) are highly correlated with the NRF2 core target signature and are significantly different compared to lower stage I tumors (*n* = 251; *p* = 0.028; KS = Kolmogorov-Smirnov test). **b)** Kaplan-Meier (KM) survival curves comparing LUAD TCGA patients stratified by their correlation with the NRF2 core target signature. Patient tumor samples were binned according to their gene expression correlation with the NRF2 signature. The top 15% (*n* = 68) correlated tumors exhibit significantly decreased survival compared to the rest (*n* = 390) of the TCGA LUAD cohort (*p* = 0.008, log-rank test). **c)** KM survival curves comparing TCGA LUAD patients stratified by their correlation with the *KEAP1*-mutant signature derived from TCGA patient expression profiles. The top 20% correlated patients (*n* = 91) exhibit decreased survival compared to the rest (*n* = 367) of the TCGA LUAD cohort (*p* = 0.012, log-rank test). **d)** Empirical cumulative distribution function (CDF) plot showing expression correlation of individual tumors with the *KEAP1*-mutant signature across various clinical stages within the TCGA LUAD cohort. Each curve represents a unique clinical stage as depicted in the figure legend. Clinical stage IV tumors (*n* = 24) are highly correlated with the *KEAP1*-mutant signature and are significantly different compared to stage I tumors (*n* = 251; *p* = 0.038, KS=Kolmogorov-Smirnov test). **e)** KM survival curves comparing TCGA LUAD patients stratified by their correlation with the murine-derived *Keap1*-mutant signature. The top 50% correlated tumors (*n* = 229) exhibit significantly decreased survival compared to the rest (*n* = 229) of the TCGA LUAD cohort (*p* \< 0.003, log-rank test).](nihms901248f2){#F2}

![CRISPR screen reveals that *Keap1*-mutant cells are glycolytic and sensitive to reduced levels of glutamine\
**a)** Pooled sgRNA library screen. Figure inlet; schematic of experiment. Cells were passaged for 14 doublings before collection. Bars represent the median differential genescore. Full representation in [Supplementary Fig 7a](#SD1){ref-type="supplementary-material"}. **b)** Western blot analysis of Slc1a5 in KP and KPK cells post selection infected with sgTom or sgSlc1a5. Hsp90 was used as a loading control. **c)** Cumulative population doublings of KP and KPK cells after transduction with sgTom or sgSlc1a5 (*n* = 4). Picture inlet; colony formation assay in KP and KPK cells transduced with sgTom or sgSlc1a5. \*\*\*\**p* \< 0.0001 obtained from 2-way ANOVA. **d)** Cumulative population doublings of *KRAS*-mutant human lung cancer cell line either *KEAP1*-WT (H2009) or *KEAP1*-mutant (A549 and H2030) after selection with sgTom or sgSLC1A5 (*n* = 4). \*\*\*\**p* \< 0.0001 obtained from 2-way ANOVA. **e)** Crystal violet stain of KP and KPK cells treated with 1mM GPNA or Vehicle for 72 hrs. **f)** Cumulative population doublings of KP and KPK cells cultured in 2.0mM or 0.5mM glutamine (*n* = 4). \*\*\*\**p* \< 0.0001 obtained from 2-way ANOVA. **g)** Glutamine consumption in KP and KPK cells measured (*n* = 3). All samples were normalized to their respective vehicle treated control. \*\**p* \< 0.01 obtained from 1-way ANOVA with Tukey\'s post hoc test. All error bars depict s.e.m.](nihms901248f3){#F3}

![*Keap1*-mutant cells display a robust sensitivity to glutaminase inhibition\
**a)** Schematic of glutamine uptake by Slc1a5 and hydrolysis of glutamine to glutamate by Gls. Inhibitors of Gls are shown in red. **b)** Relative viability assayed by cell-titer glo (relative luminescent units) on KP and KPK cells after treatment with CB-839 (left) or BPTES (right) for 72 hrs. All data points are relative to vehicle treated controls (*n* = 4 technical replicates/data point). **c)** Cumulative population doublings of KP and KPK cells in the presence of vehicle, CB-839 or BPTES (*n* = 4 technical replicates/data point) after 6 days in culture. **d)** Trypan blue exclusion viability counts of indicated human lung cancer cell lines. Each cell line was cultured in the presence of vehicle or 500nM CB-839 (*n* = 4 technical replicates/cell line). Displayed results are normalized against vehicle treated cell lines after 72 hrs of treatment. A549 and H1975 are *TP53*-wild type, all others are *TP53*-mutant. **e)** Subcutaneous tumor volumes of KP and KPK treated with vehicle or CB-839 starting from day 13 measured over time for 25 days (*n* = 6 tumors/genotype/treatment)**.** Related to [Fig 4f](#F4){ref-type="fig"}. **f)** Final tumor masses related to [Supplementary Data Fig 11b](#SD1){ref-type="supplementary-material"}. \**p* \< 0.05, \*\*\*\**p* \< 0.0001 obtained from 1-way ANOVA with Tukey\'s post hoc test. **g)** Orthotopic growth measurements of KP and KPK cells treated with vehicle or CB-839 starting from day 13 (*n* = 4 mice/genotype/treatment). Quantitation of luminescence (photon flux) in mice orthotopically transplanted with KP or KPK cells transduced with a vector expressing *Luciferase*. Relative photon flux calculated by normalizing all time points per animal to initial measurements at 10 days post transplantation. Individual groups depicted in [Supplementary Data Fig 11c](#SD1){ref-type="supplementary-material"}. \*\*\**p* \< 0.001 obtained from 2-way ANOVA. **h)** Subcutaneous tumor volumes of KP-ix (inducible GOF-*Nrf2*) treated with vehicle or CB-839 in the presence or absence of doxycycline (DOX) (*n* = 6 mice/DOX treatment). Individual groups and full experiment depicted in [Supplementary Data Fig 11d](#SD1){ref-type="supplementary-material"}. **i)** Five patient-derived xenograft (PDX) models treated with vehicle or CB-839 for the indicated amount of days. Individual groups and full experiments depicted in [Supplementary Data Fig 11g and h](#SD1){ref-type="supplementary-material"}. All error bars depict s.e.m.](nihms901248f4){#F4}
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